[HTML][HTML] Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing …
AI Duarte, E Candeias, IN Alves, D Mena… - International journal of …, 2020 - mdpi.com
Alzheimer's disease (AD) is the most common form of dementia worldwide, being
characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the …
characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the …
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
PL McClean, C Hölscher - Neuropharmacology, 2014 - Elsevier
Type 2 diabetes is a risk factor in the development of Alzheimer's disease (AD). It has been
shown that insulin signalling is desensitised in the brains of AD patients. The incretin …
shown that insulin signalling is desensitised in the brains of AD patients. The incretin …
[HTML][HTML] Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer's disease
Recent clinical and epidemiological studies support the contention that diabetes mellitus
(DM) is a strong risk factor for the development of Alzheimer's disease (AD). The use of …
(DM) is a strong risk factor for the development of Alzheimer's disease (AD). The use of …
[HTML][HTML] Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes
MJ Carranza-Naval, A Del Marco… - Frontiers in aging …, 2021 - frontiersin.org
Alzheimer's disease is the most common form of dementia, and epidemiological studies
support that type 2 diabetes (T2D) is a major contributor. The relationship between both …
support that type 2 diabetes (T2D) is a major contributor. The relationship between both …
Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase …
L Qi, L Ke, X Liu, L Liao, S Ke, X Liu, Y Wang… - European journal of …, 2016 - Elsevier
Type 2 diabetes mellitus is a risk factor for Alzheimer's disease (AD). The glucagon-like
peptide-1 analog liraglutide, a novel long-lasting incretin hormone, has been used to treat …
peptide-1 analog liraglutide, a novel long-lasting incretin hormone, has been used to treat …
[HTML][HTML] The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway
Y Bao, L Jiang, H Chen, J Zou, Z Liu… - Cellular Physiology and …, 2015 - karger.com
Background/Aims: Glucagon-like peptide-1 (GLP-1)-based drugs are being used to achieve
better glucose control in patients with type 2 diabetes, and GLP-1 mimetics such as …
better glucose control in patients with type 2 diabetes, and GLP-1 mimetics such as …
Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway
XY Liu, LX Wang, Z Chen, LB Liu - Neurological research, 2016 - Taylor & Francis
Objectives: The aim of the study was to investigate the effects of the GLP-1 analog liraglutide
on beta-amyloid (Aβ)-induced neurotoxicity in the human neuroblastoma cell line SH-SY5Y …
on beta-amyloid (Aβ)-induced neurotoxicity in the human neuroblastoma cell line SH-SY5Y …
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease
PL McClean, V Parthsarathy, E Faivre… - Journal of …, 2011 - Soc Neuroscience
Type 2 diabetes is a risk factor for Alzheimer's disease, most likely linked to an impairment of
insulin signaling in the brain. The incretin hormone glucagon-like peptide-1 (GLP-1) …
insulin signaling in the brain. The incretin hormone glucagon-like peptide-1 (GLP-1) …
[HTML][HTML] Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation …
L Qi, Z Chen, Y Wang, X Liu, X Liu, L Ke… - American Journal of …, 2017 - ncbi.nlm.nih.gov
Memory deterioration and synapse damage with accumulation of β-amyloid and
hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD). Methylglyoxal …
hyperphosphorylated tau are hallmark lesions of Alzheimer's disease (AD). Methylglyoxal …
Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats
WN Han, C Hölscher, L Yuan, W Yang, XH Wang… - Neurobiology of …, 2013 - Elsevier
Type 2 diabetes mellitus is a risk factor of Alzheimer's disease (AD), most likely linked to an
impairment of insulin signaling in the brain. Liraglutide, a novel long-lasting glucagon-like …
impairment of insulin signaling in the brain. Liraglutide, a novel long-lasting glucagon-like …